(Q36621705)

15 August 2017

Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma (English)

1 reference

15 August 2017

1 reference

2

D Cunningham

1 reference

15 August 2017

H E Ford

1

1 reference

15 August 2017

P J Ross

3

1 reference

15 August 2017

S Rao

4

1 reference

15 August 2017

G W Aherne

5

1 reference

15 August 2017

T S Benepal

6

1 reference

15 August 2017

T Price

7

1 reference

15 August 2017

A Massey

8

1 reference

15 August 2017

L Vernillet

9

1 reference

15 August 2017

G Gruia

10

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 July 2000

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

83

1 reference

15 August 2017

2

1 reference

15 August 2017

146-152

1 reference

https://scigraph.springernature.com/pub.10.1054/bjoc.2000.1192

15 August 2017

0 references

cites work

Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363476

Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363476

Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363476

Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363476

A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363476

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363476

CPT-11: clinical experience in phase I studies.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363476

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363476

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363476

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363476

ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363476

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

28 June 2018

1 reference

12 December 2020

A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors

1 reference

12 December 2020

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

12 December 2020

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units

1 reference

12 December 2020

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

12 December 2020

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

1 reference

12 December 2020

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

1 reference

12 December 2020

Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.2000.1192

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

10901362

1 reference